Standard Chemical & Pharmaceutical Co (1720) Fair Value & Analysis
Healthcare · TW · Market cap 11.3B TWD
Fair value as of: Jul 23, 2026
From 24 valuation models · updated 18 days ago
Share price −11.3% over the past month.
A solid business, screening 71% undervalued on our models.
What matters now
- The price is below even our cautious bear case (72.81 TWD). The market is more pessimistic than our downside scenario.
- Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
60‑month range 31.73 TWD – 78.70 TWD · fair‑value band 72.81 TWD – 121.35 TWD · the 56.70 TWD price screens below the 97.08 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 23, 2026.
Analysis
Standard Chemical & Pharmaceutical Co (1720) currently trades at 56.70 TWD, while our model-based Fair Value estimate is 97.08 TWD, implying the stock looks roughly 71.2% undervalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Standard Chemical & Pharmaceutical Co generated revenue of 7.0B TWD at a net margin of 13.7%. Revenue grew 0.7% year over year. It earns a return on equity of 14.5%. The balance sheet holds a net cash position of 506M TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 72.81 TWD (bear case) to 121.35 TWD (bull case); at 56.70 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 15% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 71%, 1720 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (136.51 TWD) versus Asset-Based (22.96 TWD). Highest evidence: Growth DCF (80).
Notify me when 1720 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 57 · Market factors (momentum, volatility) 52
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Standard Chemical & Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceutical products in Taiwan and internationally. The company offers Chinese and western medicines, cosmetics, beverages, general instruments, and medical devices.
Full company description
Standard Chemical & Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceutical products in Taiwan and internationally. The company offers Chinese and western medicines, cosmetics, beverages, general instruments, and medical devices. It also provides western pharmaceuticals for cardiovascular, metabolic, genitourinary and sex steroids, respiratory, musculoskeletal, digestive, nervous, and circulatory systems; anti-infectives and topical medications; and cancer and cancer antiemetic. In addition, the company offers health food products. Further, it is involved in the manufacture and sale of active pharmaceutical ingredients, as well as veterinary drugs; and sales of medical devices and infant milk powder. It also exports its products. The company was incorporated in 1967 and is headquartered in Tainan City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Standard Chemical & Pharmaceutical Co reported revenue of 7.0B TWD in FY2025 versus 4.6B TWD in FY2021, a compound +11.1%/yr. Reported net income was 928M TWD in FY2025, compounding +7.0%/yr from FY2021.
of which total revenue +7.7 pp · buybacks/dilution −1.3 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 1720: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Standard Chemical & Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Standard Chemical & Pharmaceutical Co (1720) overvalued or undervalued?
What is the fair value of 1720?
What is the quality score of 1720?
What is the revenue of Standard Chemical & Pharmaceutical Co (1720)?
What is the net profit margin of 1720?
Does Standard Chemical & Pharmaceutical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Standard Chemical & Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.